AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15744348 — intervention group
Group type: COMPARATOR
Intervention: No intravenous 6-mercaptopurine (Control Group, Arm A)
Number of subjects: 877
Study 12173072 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 20 mg once a day for two days prior to HA and during initial three days at HA
Number of subjects: 40
Study 12173072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9458539 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (GRA)
Number of subjects: 90
Study 9458539 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron plus prednisolone (GRA + PRE)
Number of subjects: 90
Study 7889578 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%
Number of subjects: 30
Study 7889578 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 30
Study 2218831 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin
Number of subjects: 96
Study 2218831 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin plus tobramycin
Number of subjects: 96
Study 91437 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose cis-platinum (1-hour infusion with mannitol diuresis)
Number of subjects: 45
Study 91437 — intervention group
Group type: COMPARATOR
Intervention: Low dose cis-platinum (8-hour infusion without diuresis)
Number of subjects: 45
Study 91437 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-drug program (vinblastine, actinomycin D, and cis-platinum)
Number of subjects: 45
Study 91437 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic crossover regimen (three regimens each containing three drugs)
Number of subjects: 45
Study 91437 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited-disease patients
Number of subjects: 45
Study 91437 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced-disease patients
Number of subjects: 45
Study 30854443 — intervention group
Group type: EXPERIMENTAL
Intervention: DCE-MRI before radiation therapy (pre-RT)
Number of subjects: 62
Study 30854443 — intervention group
Group type: EXPERIMENTAL
Intervention: DCE-MRI after 2 weeks of radiation therapy (2wkRT)
Number of subjects: 62
Study 30854443 — intervention group
Group type: EXPERIMENTAL
Intervention: DCE-MRI assessment
Number of subjects: 62
Study 27657674 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab (8 mg/kg) plus best supportive care
Number of subjects: 643
Study 27657674 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus best supportive care
Number of subjects: 643
Study 27657674 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 643
Study 25461393 — intervention group
Group type: EXPERIMENTAL
Intervention: alendronate 70mg weekly
Number of subjects: 18
Study 25461393 — intervention group
Group type: EXPERIMENTAL
Intervention: zoledronate (10(‐9)‐10(‐6)M)
Number of subjects: 18
Study 25461393 — intervention group
Group type: EXPERIMENTAL
Intervention: alendronate (10(‐7) and 10(‐6))
Number of subjects: 18
Study 25461393 — intervention group
Group type: EXPERIMENTAL
Intervention: zoledronate (10(‐10)‐10(‐6)M)
Number of subjects: 18
Study 25461393 — intervention group
Group type: EXPERIMENTAL
Intervention: calcitriol (10(‐8)M)
Number of subjects: 18
Study 22991162 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive Writing Intervention (EWI) - emotional disclosure
Number of subjects: 507
Study 22991162 — intervention group
Group type: COMPARATOR
Intervention: Control group - non-emotional topic
Number of subjects: 507
Study 21427113 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR <45
Number of subjects: 2967
Study 20128296 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle‐pricking bleeding combined with pulling‐rotating manipulation
Number of subjects: 198
Study 20128296 — intervention group
Group type: COMPARATOR
Intervention: Simple pulling‐rotating manipulation (Control)
Number of subjects: 198
Study 17095896 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 27
Study 17095896 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 27
Study 15536656 — intervention group
Group type: EXPERIMENTAL
Intervention: New parameter for measuring sagging amplitude of submental skin
Number of subjects: 66
Study 10772372 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized follow-up (weekly telephone contact for 12 weeks)
Number of subjects: 30
Study 10772372 — intervention group
Group type: COMPARATOR
Intervention: Control group (no personalized follow-up)
Number of subjects: 30
Study 9001919 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental tobacco smoke (ETS) exposure (20 ppm CO) for 3 hours (7:00 to 10:00 p.m.)
Number of subjects: 17
Study 9001919 — intervention group
Group type: COMPARATOR
Intervention: Ambient air (sham) exposure for 3 hours (7:00 to 10:00 p.m.)
Number of subjects: 17
Study 8877210 — intervention group
Group type: EXPERIMENTAL
Intervention: Lens tube
Number of subjects: 72
Study 8877210 — intervention group
Group type: COMPARATOR
Intervention: Donaldson tube
Number of subjects: 72
Study 3537249 — intervention group
Group type: EXPERIMENTAL
Intervention: Methionyl human growth hormone (0.125 mg/kg three times per week)
Number of subjects: 70
Study 3537249 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone (0.125 mg/kg/day)
Number of subjects: 70
Study 3537249 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (hGH plus oxandrolone)
Number of subjects: 70
Study 3537249 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 70
Study 31195408 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted BMI
Number of subjects: 367703
Study 31195408 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted fat mass index
Number of subjects: 367703
Study 31195408 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted fat-free mass index
Number of subjects: 367703
Study 31467392 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 12
Study 31467392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 28222552 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to daily Occupational Performance (CO‐OP) approach
Number of subjects: 43
Study 28222552 — intervention group
Group type: COMPARATOR
Intervention: Conventional occupational therapy
Number of subjects: 43
Study 25938886 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (50,000 IU every 2 weeks from 20 to 32 weeks of gestation)
Number of subjects: 60
Study 23761202 — intervention group
Group type: EXPERIMENTAL
Intervention: Liveonline aftercare program (6 units comprehensive multimodal)
Number of subjects: 0
Study 23761202 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care not specified)
Number of subjects: 0
Study 23761202 — intervention group
Group type: EXPERIMENTAL
Intervention: Liveonline aftercare program
Number of subjects: 0
Study 21601839 — intervention group
Group type: EXPERIMENTAL
Intervention: Judgments based on the agent's innocent intent regarding accidental harms.
Number of subjects: 0
Study 21601839 — intervention group
Group type: EXPERIMENTAL
Intervention: Judgments based on the agent's guilty intent regarding failed attempts to harm.
Number of subjects: 0
Study 19139333 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine plus plano lens
Number of subjects: 180
Study 19139333 — intervention group
Group type: COMPARATOR
Intervention: Atropine alone
Number of subjects: 180
Study 17003082 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg once daily
Number of subjects: 80
Study 17003082 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin 10 mg every other day
Number of subjects: 80
Study 15041559 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial splenic embolization with gelatin sponge particles (60%-80% embolized volume)
Number of subjects: 45
Study 15041559 — intervention group
Group type: COMPARATOR
Intervention: Partial splenic embolization with gelatin sponge particles (40%-60% embolized volume)
Number of subjects: 45
Study 15041559 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial splenic embolization (both groups)
Number of subjects: 45
Study 11357028 — intervention group
Group type: EXPERIMENTAL
Intervention: Diathermy hemorrhoidectomy
Number of subjects: 50
Study 11357028 — intervention group
Group type: COMPARATOR
Intervention: Harmonic Scalpel hemorrhoidectomy
Number of subjects: 50
Study 9206959 — intervention group
Group type: EXPERIMENTAL
Intervention: Stomach ulcer
Number of subjects: 71
Study 9206959 — intervention group
Group type: COMPARATOR
Intervention: Duodenal ulcer
Number of subjects: 71
Study 8196788 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative instruction and physical therapy
Number of subjects: 64
Study 8196788 — intervention group
Group type: COMPARATOR
Intervention: No preoperative instruction and physical therapy
Number of subjects: 64
Study 3359548 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-residue diet with an additional intake of 1200 Kcal and 32 g protein daily (Group B)
Number of subjects: 24
Study 3359548 — intervention group
Group type: COMPARATOR
Intervention: Uninterrupted colonic preparation with dietary restrictions for 4-8 days (450 calories; 25 g proteins daily) (Group A)
Number of subjects: 24
Study 29952297 — intervention group
Group type: EXPERIMENTAL
Intervention: Cal/BD foam
Number of subjects: 463
Study 28150971 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 110
Study 28150971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 26187378 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimised patient information materials
Number of subjects: 2035
Study 26187378 — intervention group
Group type: COMPARATOR
Intervention: Standard patient information materials
Number of subjects: 2035
Study 22890567 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone graft (BG) from the iliac crest
Number of subjects: 107
Study 22890567 — intervention group
Group type: COMPARATOR
Intervention: No bone graft (NBG)
Number of subjects: 107
Study 20925067 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole 0.5 mg bid
Number of subjects: 311
Study 20925067 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole 0.75 mg bid
Number of subjects: 311
Study 20925067 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole 0.5 mg tid
Number of subjects: 311
Study 20925067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311
Study 19503030 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle structure scintillator with 40% reduction of exposure
Number of subjects: 296
Study 19503030 — intervention group
Group type: COMPARATOR
Intervention: Granular structure scintillator
Number of subjects: 296
Study 16740918 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (pPCI)
Number of subjects: 1319
Study 16740918 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic treatment (TT)
Number of subjects: 1319
Study 15541014 — intervention group
Group type: EXPERIMENTAL
Intervention: Atipamezole (three-step infusion aiming for serum concentrations of 10, 30, and 90 ng ml(‐1))
Number of subjects: 6
Study 15541014 — intervention group
Group type: EXPERIMENTAL
Intervention: Atipamezole (three-step infusion)
Number of subjects: 6
Study 11555222 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based teaching package
Number of subjects: 166
Study 11555222 — intervention group
Group type: COMPARATOR
Intervention: Lecture
Number of subjects: 166
Study 11555222 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Computer-based and Lecture)
Number of subjects: 166
Study 9433582 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascertainment scheme with exactly two affected sibs
Number of subjects: 0
Study 9433582 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascertainment scheme with two sibs who had extremely discordant values for Q1
Number of subjects: 0
Study 9433582 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascertainment scheme with sib pairs extremely discordant for Q2
Number of subjects: 0
Study 9433582 — intervention group
Group type: EXPERIMENTAL
Intervention: Random ascertainment scheme
Number of subjects: 0
Study 9433582 — intervention group
Group type: COMPARATOR
Intervention: Affected sib pairs or sib pairs with extremely discordant values for Q1
Number of subjects: 0
Study 8491246 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitecapone 100 mg t.d.s. for 7 days
Number of subjects: 15
Study 3555605 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% idoxuridine ointment applied twice daily for 2 weeks
Number of subjects: 24
Study 3555605 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment applied twice daily for 2 weeks
Number of subjects: 24
Study 30032937 — intervention group
Group type: COMPARATOR
Intervention: Individually-based treatment (IBT)
Number of subjects: 61
Study 30032937 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral couples therapy plus individually-based treatment (BCT + IBT)
Number of subjects: 61
Study 27311248 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide (subcutaneous 0.75 or 1.5 mg once weekly)
Number of subjects: 0
Study 27311248 — intervention group
Group type: COMPARATOR
Intervention: Metformin, sitagliptin, exenatide, insulin glargine
Number of subjects: 0
Study 27311248 — intervention group
Group type: COMPARATOR
Intervention: Liraglutide 1.8 mg once daily
Number of subjects: 0
Study 25333428 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental care provided by a dental surgeon, 4‐5 times a week, including routine oral hygiene, teeth brushing, tongue scraping, removal of calculus, atraumatic restorative treatment of caries, and tooth extraction
Number of subjects: 254
Study 25333428 — intervention group
Group type: COMPARATOR
Intervention: Routine oral hygiene only, including the use of chlorhexidine as a mouth rinse, performed by ICU nurse staff
Number of subjects: 254
Study 25333428 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental care provided by a dental surgeon
Number of subjects: 254
Study 25333428 — intervention group
Group type: COMPARATOR
Intervention: Routine oral hygiene only
Number of subjects: 254
Study 23373662 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of opportunistic infections prophylaxis
Number of subjects: 74
Study 23373662 — intervention group
Group type: COMPARATOR
Intervention: Continuation of opportunistic infections prophylaxis
Number of subjects: 74
Study 20952013 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA 100 U or greater
Number of subjects: 313
Study 20952013 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Number of subjects: 313
Study 20952013 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 313
Study 18662285 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg oxazepam
Number of subjects: 8
Study 18662285 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg oxazepam
Number of subjects: 8
Study 21321086 — intervention group
Group type: EXPERIMENTAL
Intervention: Motesanib 125 mg once daily (qd)
Number of subjects: 186
Study 21321086 — intervention group
Group type: EXPERIMENTAL
Intervention: Motesanib 75 mg twice daily (b.i.d.) 5 days on/2 days off
Number of subjects: 186
Study 21321086 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab 15 mg/kg every 3 weeks (q3w)
Number of subjects: 186
Study 15933353 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-prescription of heroin (inhalable or injectable) over 12 months
Number of subjects: 430
Study 15933353 — intervention group
Group type: COMPARATOR
Intervention: Methadone alone (maximum 150 mg a day)
Number of subjects: 430
Study 12131942 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular diclofenac, 75 mg associated with intravenous physiological saline, 10 ml
Number of subjects: 120
Study 12131942 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline alone (placebo)
Number of subjects: 120
Study 12131942 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular diclofenac
Number of subjects: 120
Study 9796841 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (ACE inhibitor)
Number of subjects: 10500
Study 9796841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10500
Study 7639004 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiation therapy
Number of subjects: 68
Study 7639004 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (Control)
Number of subjects: 68
Study 2468183 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent ifosfamide
Number of subjects: 98
Study 2468183 — intervention group
Group type: EXPERIMENTAL
Intervention: BIP combination (ifosfamide, cisplatin, and bleomycin)
Number of subjects: 98
Study 871634 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg prazosin with 100 mmol sodium intake
Number of subjects: 7
Study 871634 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg prazosin with 100 mmol sodium intake
Number of subjects: 7
Study 871634 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg prazosin with 250 mmol sodium intake
Number of subjects: 7
Study 871634 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg prazosin with 250 mmol sodium intake
Number of subjects: 7
Study 871634 — intervention group
Group type: COMPARATOR
Intervention: High sodium intake (250 mmol)
Number of subjects: 7
Study 11425770 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin alone
Number of subjects: 135
Study 11425770 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin alone
Number of subjects: 135
Study 11425770 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Aspirin and Warfarin)
Number of subjects: 135
Study 11425770 — intervention group
Group type: COMPARATOR
Intervention: Control (Placebo + Warfarin)
Number of subjects: 135
Study 11425770 — intervention group
Group type: COMPARATOR
Intervention: Control (Placebo + Aspirin)
Number of subjects: 135
Study 30664736 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (LCD) plus walking
Number of subjects: 42
Study 30664736 — intervention group
Group type: COMPARATOR
Intervention: Control (usual diet and exercise)
Number of subjects: 42
Study 30021096 — intervention group
Group type: EXPERIMENTAL
Intervention: l-glutamine (0.3 g/kg per dose, administered twice daily)
Number of subjects: 230
Study 30021096 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 230
Study 26718379 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (940-nm gallium-aluminum-arsenic diode laser, 200 mW, 20 seconds at 3 points on buccal mucosa)
Number of subjects: 88
Study 26718379 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser therapy (laser not turned on)
Number of subjects: 88
Study 25290091 — intervention group
Group type: EXPERIMENTAL
Intervention: dalotuzumab/MK‐2206
Number of subjects: 47
Study 25290091 — intervention group
Group type: EXPERIMENTAL
Intervention: dalotuzumab/MK‐0752
Number of subjects: 47
Study 22581038 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosafe decision support system
Number of subjects: 12
Study 22581038 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 12
Study 22581038 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific carbohydrate absorption factor
Number of subjects: 12
Study 22581038 — intervention group
Group type: EXPERIMENTAL
Intervention: BG-dependent variable insulin appearance rate
Number of subjects: 12
Study 20350695 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular pacing (BiVP)
Number of subjects: 60
Study 20350695 — intervention group
Group type: COMPARATOR
Intervention: Right ventricular pacing (RVP)
Number of subjects: 60
Study 17275636 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin dosing by nomogram
Number of subjects: 216
Study 17275636 — intervention group
Group type: COMPARATOR
Intervention: Warfarin dosing by house staff
Number of subjects: 216
Study 16206365 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient self-report instrument
Number of subjects: 0
Study 16206365 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigator instrument
Number of subjects: 0
Study 16206365 — intervention group
Group type: COMPARATOR
Intervention: Current methods of adverse event reporting
Number of subjects: 0
Study 16206365 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient instrument
Number of subjects: 0
Study 16206365 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrument development
Number of subjects: 0
Study 12851279 — intervention group
Group type: EXPERIMENTAL
Intervention: Tifacogin (0.025 mg/kg per hour for 96 hours, n = 880)
Number of subjects: 1754
Study 12851279 — intervention group
Group type: COMPARATOR
Intervention: Placebo (arginine citrate buffer, n = 874)
Number of subjects: 1754
Study 12851279 — intervention group
Group type: EXPERIMENTAL
Intervention: Tifacogin (n = 722)
Number of subjects: 1754
Study 12851279 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 722)
Number of subjects: 1754
Study 12851279 — intervention group
Group type: EXPERIMENTAL
Intervention: Tifacogin (low INR, n = 83)
Number of subjects: 1754
Study 12851279 — intervention group
Group type: COMPARATOR
Intervention: Placebo (low INR, n = 118)
Number of subjects: 1754
Study 12851279 — intervention group
Group type: EXPERIMENTAL
Intervention: Tifacogin
Number of subjects: 1754
Study 12851279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1754
Study 12851279 — intervention group
Group type: EXPERIMENTAL
Intervention: Tifacogin (low INR)
Number of subjects: 1754
Study 12851279 — intervention group
Group type: COMPARATOR
Intervention: Placebo (low INR)
Number of subjects: 1754
Study 10536644 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion at incremental doses from 0.010 to 0.030 microgram kg‐1 min‐1
Number of subjects: 36
Study 10536644 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion
Number of subjects: 36
Study 8902992 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with myocardial infarction
Number of subjects: 38
Study 8902992 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 38
Study 1867449 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breast feeding for greater than 4 months
Number of subjects: 288
Study 1867449 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow milk whey hydrolysate formula (NAN/HA)
Number of subjects: 288
Study 1867449 — intervention group
Group type: COMPARATOR
Intervention: Conventional cow milk formula (Similac)
Number of subjects: 288